Specialist to lead North American Operations

Nick Moore, PhD has been appointed to head up business development in North America for drug discovery development and compound services management company BioAscent.

An internationally recognised specialist Dr Moore has directed a range of drug discovery programs spanning multiple therapeutic indications, including leading the preclinical development of the $5bn blockbuster Zyprexa (olanzapine) for Eli Lilli. He has held senior roles in the US and the UK, with both in-house and contract research organisation experience, most recently including Charles River Discovery Services.

“Working with customers varying from the smallest academic spin-out to large pharma, and being able to offer customised services to meet their exact requirements was a real draw for me,” said Dr Moore. “BioAscent’s capabilities in drug discovery and compound management are an especially good fit with VC-funded biotechs, because we offer a rare mix of leading infrastructure and scientific excellence. We can really contribute scientifically to their project teams, and also provide compound management expertise to ensure that the right compounds are shipped to the right place, at the right time, in the right format - and in the most cost-effective and trackable way.”

Paul Smith, BioAscent’s CEO said: “Having state-of-the-art facilities and a broad range of services are really important to BioAscent’s offering, however it’s the excellence of our people that makes the real difference to our customers. Nick’s track record in drug discovery and development, including being a recipient of the prestigious 'Society for Medicines Research Award for Drug Discovery', is a clear demonstration of our policy of hiring the best people and we look forward to further expanding our customer base in North America.”